XMRV and prostate cancerg - A 'final' perspective

Karen S. Sfanos, Amanda L. Aloia, Angelo M. De Marzo, Alan Rein

Research output: Contribution to journalReview articlepeer-review

Abstract

XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalNature Reviews Urology
Volume9
Issue number2
DOIs
StatePublished - Feb 2012

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'XMRV and prostate cancerg - A 'final' perspective'. Together they form a unique fingerprint.

Cite this